This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Non-Hodgkin lymphoma
  • /
  • Increasing the efficacy of CD20 antibody therapy t...
Journal

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

Read time: 1 mins
Published:3rd Jun 2010
Author: Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al.
Source: Blood
Ref.:Blood. 2010;115:4393-402.
DOI:10.1182/blood-2009-06-225979.
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest